RT Journal Article
SR Electronic
T1 Remdesivir for the treatment of hospitalised patients with COVID-19: final results from the DisCoVeRy randomised, controlled, open-label trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.30.22273206
DO 10.1101/2022.03.30.22273206
A1 Ader, Florence
A1 Bouscambert-Duchamp, Maude
A1 Hites, Maya
A1 Peiffer-Smadja, Nathan
A1 Poissy, Julien
A1 Belhadi, Drifa
A1 Diallo, Alpha
A1 Delmas, Christelle
A1 Saillard, Juliette
A1 Dechanet, Aline
A1 Fougerou, Claire
A1 Lê, Minh-Patrick
A1 Peytavin, Gilles
A1 Mercier, Noémie
A1 Velou, Priyanka
A1 Tubiana, Sarah
A1 Lescure, Xavier
A1 Faure, Emmanuel
A1 Nseir, Saad
A1 Richard, Jean-Christophe
A1 Wallet, Florent
A1 Goehringer, François
A1 Lefèvre, Benjamin
A1 Kimmoun, Antoine
A1 Raffi, François
A1 Gaborit, Benjamin
A1 Reignier, Jean
A1 Lanoix, Jean-Philippe
A1 Andrejak, Claire
A1 Zerbib, Yoann
A1 Bani-Sadr, Firouzé
A1 Mourvilliers, Bruno
A1 Danion, François
A1 Ruch, Yvon
A1 Clere-Jehl, Raphaël
A1 Le Moing, Vincent
A1 Klouche, Kada
A1 Lacombe, Karine
A1 Martin-Blondel, Guillaume
A1 Vardon-Bounes, Fanny
A1 Cabié, André
A1 Turmel, Jean-Marie
A1 Piroth, Lionel
A1 Blot, Mathieu
A1 Botelho-Nevers, Élisabeth
A1 Gagneux-Brunon, Amandine
A1 Thiery, Guillaume
A1 Bénézit, François
A1 Gaci, Rostane
A1 Mootien, Joy
A1 Gallien, Sébastien
A1 Garot, Denis
A1 Bouiller, Kevin
A1 Epelboin, Loïc
A1 Jauréguiberry, Stéphane
A1 Gaymard, Alexandre
A1 Verschelden, Gil
A1 Braz, Sandra
A1 Ferreira Ribeiro, Joao Miguel
A1 Joannidis, Michael
A1 Staub, Thérèse
A1 Altdorfer, Antoine
A1 Greil, Richard
A1 Egle, Alexander
A1 Guedj, Jérémie
A1 Noret, Marion
A1 Roncon-Albuquerque, Roberto
A1 Paiva, Jose-Artur
A1 Lina, Bruno
A1 Costagliola, Dominique
A1 Yazdanpanah, Yazdan
A1 Burdet, Charles
A1 Mentré, France
YR 2022
UL http://medrxiv.org/content/early/2022/04/12/2022.03.30.22273206.abstract
AB Background The antiviral efficacy of remdesivir is still controversial. We aimed at evaluating its clinical effectiveness in hospitalised patients with COVID-19, with indication of oxygen and/or ventilator support. Following prior publication of preliminary results, here we present the final results after completion of data monitoring.Methods In this European multicentre, open-label, parallel-group, randomised, controlled trial (DisCoVeRy, NCT04315948; EudraCT2020-000936-23), participants were randomly allocated to receive usual standard of care (SoC) alone or in combination with remdesivir, lopinavir/ritonavir, lopinavir/ritonavir and IFN-β-1a, or hydroxychloroquine. Adult patients hospitalised with COVID-19 were eligible if they had clinical evidence of hypoxemic pneumonia, or required oxygen supplementation. Exclusion criteria included elevated liver enzyme, severe chronic kidney disease, any contra-indication to one of the studied treatments or their use in the 29 days before randomization, or use of ribavirin, as well as pregnancy or breast-feeding. Here, we report results for remdesivir + SoC versus SoC alone. Remdesivir was administered as 200 mg infusion on day 1, followed by once daily infusions of 100 mg up to 9 days, for a total duration of 10 days. It could be stopped after 5 days if the participant was discharged. Treatment assignation was performed via web-based block randomisation stratified on illness severity and administrative European region. The primary outcome was the clinical status at day 15 measured by the WHO 7-point ordinal scale, assessed in the intention-to-treat population.Findings Between March 22nd, 2020 and January 21st, 2021, 857 participants were randomised to one of the two arms in 5 European countries and 843 participants were included for the evaluation of remdesivir (control, n=423; remdesivir, n=420).At day 15, the distribution of the WHO ordinal scale was as follow in the remdesivir and control groups, respectively: Not hospitalized, no limitations on activities: 62/420 (14.8%) and 72/423 (17.0%); Not hospitalized, limitation on activities: 126/420 (30%) and 135/423 (31.9%); Hospitalized, not requiring supplemental oxygen: 56/420 (13.3%) and 31/423 (7.3%); Hospitalized, requiring supplemental oxygen: 75/420 (17.9%) and 65/423 (15.4%); Hospitalized, on non-invasive ventilation or high flow oxygen devices: 16/420 (3.8%) and 16/423 (3.8%); Hospitalized, on invasive mechanical ventilation or ECMO: 64/420 (15.2%) and 80/423 (18.9%); Death: 21/420 (5%) and 24/423 (5.7%). The difference between treatment groups was not statistically significant (OR for remdesivir, 1.02, 95% CI, 0.62 to 1.70, P=0.93). There was no significant difference in the occurrence of Serious Adverse Events between treatment groups (remdesivir, n=147/410, 35.9%, versus control, n=138/423, 32.6%, p=0.29).Interpretation Remdesivir use for the treatment of hospitalised patients with COVID-19 was not associated with clinical improvement at day 15.Funding European Union Commission, French Ministry of Health, DIM One Health Île-de-France, REACTing, Fonds Erasme-COVID-ULB; Belgian Health Care Knowledge Centre (KCE), AGMT gGmbH, FEDER “European Regional Development Fund”, Portugal Ministry of Health, Portugal Agency for Clinical Research and Biomedical Innovation. Remdesivir was provided free of charge by Gilead.Competing Interest StatementDr. Costagliola reports grants and personal fees from Janssen, personal fees from Gilead, outside the submitted work. Dr. Mentre reports grants from INSERM Reacting (French Government), grants from Ministry of Health (French Government), grants from European Commission, during the conduct of the study; grants from Sanofi, grants from Roche, outside the submitted work. Dr. Hites reports grants from The Belgian Center for Knowledge (KCE), grants from Fonds Erasme-COVID-ULB, during the conduct of the study; personal fees from Gilead, outside the submitted work. Dr. Mootien reports non-financial support from GILEAD, outside the submitted work. Dr. Gaborit reports non-financial support from Gilead, non-financial support from MSD, outside the submitted work. Dr. Botelho-Nevers reports other from Pfizer, other from Janssen, outside the submitted work. Dr. Lacombe reports personal fees and non-financial support from Gilead, personal fees and non-financial support from Janssen, personal fees and non-financial support from MSD, personal fees and non-financial support from ViiV Healthcare, personal fees and non-financial support from Abbvie, during the conduct of the study. Dr. Wallet reports personal fees and non-financial support from Jazz pharmaceuticals, personal fees and non-financial support from Novartis, personal fees and non-financial support from Kite-Gilead, outside the submitted work. Dr. Kimmoun reports personal fees from Aguettan, personal fees from Aspen, outside the submitted work. Dr. Thiery reports personal fees from AMGEN, outside the submitted work. Dr. Burdet reports personal fees from Da Volterra, personal fees from Mylan Pharmaceuticals, outside the submitted work. Dr. Poissy reports personal fees from Gilead for lectures, outside the submitted work. Dr. Goehringer reports personal fees from Gilead Sciences, non-financial support from Gilead Sciences, grants from Biomerieux, non-financial support from Pfizer, outside the submitted work. Dr. Peytavin reports personal fees from Gilead Sciences, personal fees from Merck France, personal fees from ViiV Healthcare, personal fees from TheraTechnologies, outside the submitted work. Dr. Danion reports personal fees from Gilead, outside the submitted work. Dr. Raffi reports personal fees from Gilead, personal fees from Janssen, personal fees from MSD, personal fees from Abbvie, personal fees from ViiV Healthcare, personal fees from Theratechnologies, personal fees from Pfizer, outside the submitted work. Dr. Gallien reports personal fees from Gilead, personal fees from Pfizer, personal fees from ViiV, personal fees from MSD, outside the submitted work; and has received consulting fee from Gilead in August 2020 to check the registration file of remdesivir for the French administration. Dr. Nseir reports personal fees from MSD, personal fees from Pfizer, personal fees from Gilead, personal fees from Biomerieux, personal fees from BioRad, outside the submitted work. Dr. Lefevre reports personal fees from Mylan, personal fees from Gilead, outside the submitted work. Dr. Guedj reports personal fees from Roche, outside the submitted work. Other authors have nothing to disclose.Clinical TrialNCT04315948Funding StatementThis work received funding from several sources: Europe: European Union Horizon 2020 research and innovation programme Austria: AGMT gGmbH Belgium: Belgian Health Care Knowledge Centre; Fonds Erasme-COVID-ULB France: REACTing, a French multi-disciplinary collaborative network working on emerging infectious diseases; Ministry of Health; Paris Ile-de-France Region Luxemburg: European Regional Development Fund Portugal: Ministry of Health; Agency for Clinical Research and Biomedical Innovation Remdesivir was provided by Gilead free of charge. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Centre de Protection des Personnes Ile-de-France-III, approval #20.03.06.51744I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsAll data produced in the present study are available upon reasonable request to the authors